Table 3.
Parameter estimates and bootstrap results for the PFS models
| Parameters | Population estimate (%SEE) | Bootstrap parameter results (5–95 Percentile) | ||
|---|---|---|---|---|
| Cmin1 model | Cavg model | Cmin1 model | Cavg model | |
| Baseline hazard | ||||
| BaseHazard | 0.00604 (2–52) | 0.00616 (2.63) | 0.00607 (0.00473–0.00786) |
0.00619 (0.00476–0.00805) |
| Olaratumab effect | ||||
| EMAX | 0.571 (15–4) | 0.614 (14.5) | 0.567 (0.363–0.723) | 0.617 (0.435–0.770) |
| ECmin150 (µg/mL) | 82.0 (6–15) | – | 82.3 (69.3–95.4) | |
| ECavg50 (µg/mL) | – | 179 (9.33) | 182 (149–241) | |
| Hill | 8 (fixed) | 8 (fixed) | 8 (fixed) | 8 (fixed) |
PFS progression-free survival, SEE standard error of the estimate, Cmin1 trough serum concentration at the end of Cycle 1, Cavg average concentration over patient’s entire treatment, EMAXmaximum response achievable from a dose, ECmin150 olaratumab Cmin1 yielding a 50% decrease in the baseline hazard, ECavg50 olaratumab Cavg yielding a 50% decrease in the baseline hazard